Your search returned 7 studies. (Get alerts for new studies):
- Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymp
Conditions: Lymphoma, Large-Cell, Diffuse
6 Locations available
- An SGN-35 Trial for Patients Who Have Previously Participated in an SGN-35 Study
Conditions: Disease, Hodgkin - Lymphoma, Large-Cell, Anaplastic - Lymphoma, Non-Hodgkin
15 Locations available
- Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
Conditions: NHL - Lymphoma, Non-Hodgkin - Lymphoma, B-Cell - Lymphoma, Follicular - Lymphoma, Intermediate-Grade - Lymphoma, Large-Cell - Lymphoma, Low-Grade - Lymphoma, Mixed-Cell - Lymphoma, Small-Cell - Leukemia, Lymphocytic, Chronic - Leukemia, B-Cell, Chronic -
4 Locations available
- A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Conditions: Systemic Anaplastic Large-Cell Lymphoma - Neoplasms - Anaplastic Lymphoma Kinase, Human - NSCLC
9 Locations available
- A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neopl
Conditions: Lymphoma, Large-Cell, Anaplastic - Lymphoma, NK-cell - Lymphoma, T-cell
9 Locations available
- Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Conditions: Diffuse Large B-Cell Lymphoma - Lymphoma, Diffuse Large-Cell - Diffuse Large-Cell Lymphoma - Lymphoma
7 Locations available
- Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Conditions: Hodgkin Lymphoma - Anaplastic Large-cell Lymphoma
3 Locations available
|